QRON
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was incorporated in 2016 and is based in Long Island City, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q4 | 0.01 | $0 | -$2,479 |
| 2024 Q3 | -0.00 | $0 | -$28,069 |
| 2024 Q2 | -0.01 | $0 | -$11,930 |
| 2024 Q1 | -0.00 | $0 | -$19,283 |
| 2023 Q4 | -0.01 | $0 | -$20,226 |
| 2023 Q3 | -0.04 | $0 | -$19,499 |
| 2023 Q2 | -0.00 | $0 | -$15,343 |
| 2023 Q1 | -0.01 | $0 | -$13,581 |